CSBR (Champions Oncology) Cyclically Adjusted Book per Share: $0.32 (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.17
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Cyclically Adjusted Book per Share?

Champions Oncology CSBR -3.02% 64 Cyclically Adjusted Book per Share is $0.32 as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Champions Oncology's adjusted book value per share for the three months ended in Jan. 2026 was $0.308. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.32 for the trailing ten years ended in Jan. 2026.

During the past 12 months, Champions Oncology's average Cyclically Adjusted Book Growth Rate was -13.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -6.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Champions Oncology was 56.30% per year. The lowest was -14.60% per year. And the median was 7.45% per year.

As of today (2026-06-29), Champions Oncology's current stock price is $6.17. Champions Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2026 was $0.32. Champions Oncology's Cyclically Adjusted PB Ratio of today is 19.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Champions Oncology was 47.39. The lowest was 3.52. And the median was 18.40.


Champions Oncology  (NAS:CSBR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Champions Oncology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.17/0.32
=19.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Champions Oncology was 47.39. The lowest was 3.52. And the median was 18.40.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Champions Oncology Cyclically Adjusted Book per Share Related Terms


Champions Oncology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Cyclically Adjusted Book per Share Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.43 0.47 0.32 0.35

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.35 0.33 0.33 0.32

CSBR vs SEER, RLYB, FBIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted PB Ratio falls into.


CSBR
64GF Score
Champions Oncology Inc CSBR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Champions Oncology's adjusted Book Value per Share data for the three months ended in Jan. 2026 was:

Adj_Book= Book Value per Share /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=0.308/325.2520*325.2520
=0.308

Current CPI (Jan. 2026) = 325.2520.

Champions Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201604 0.027 239.261 0.037
201607 0.290 240.628 0.392
201610 0.292 241.729 0.393
201701 0.186 242.839 0.249
201704 0.036 244.524 0.048
201707 0.026 244.786 0.035
201710 0.034 246.663 0.045
201801 0.043 247.867 0.056
201804 0.000 250.546 0.000
201807 0.055 252.006 0.071
201810 0.174 252.885 0.224
201901 0.200 251.712 0.258
201904 0.193 255.548 0.246
201907 0.149 256.571 0.189
201910 0.182 257.346 0.230
202001 0.269 257.971 0.339
202004 0.401 256.389 0.509
202007 0.433 259.101 0.544
202010 0.516 260.388 0.645
202101 0.588 261.582 0.731
202104 0.554 267.054 0.675
202107 0.562 273.003 0.670
202110 0.598 276.589 0.703
202201 0.683 281.148 0.790
202204 0.673 289.109 0.757
202207 0.664 296.276 0.729
202210 0.676 298.012 0.738
202301 0.521 299.170 0.566
202304 0.342 303.363 0.367
202307 0.141 305.691 0.150
202310 0.007 307.671 0.007
202401 -0.151 308.417 -0.159
202404 -0.140 313.548 -0.145
202407 -0.024 314.540 -0.025
202410 0.050 315.664 0.052
202501 0.399 317.671 0.409
202504 0.274 320.795 0.278
202507 0.254 323.048 0.256
202510 0.300 0.000
202601 0.308 325.252 0.308

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.32 mean?
Champions Oncology (CSBR) has a Cyclically Adjusted Book per Share of $0.32 as of Jan. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Cyclically Adjusted Book per Share too high?
Champions Oncology's current Cyclically Adjusted Book per Share is $0.32. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Cyclically Adjusted Book per Share compare to SEER and RLYB?
Champions Oncology's Cyclically Adjusted Book per Share of $0.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Champions Oncology and its competitors. Champions Oncology's current Cyclically Adjusted Book per Share is $0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.17 — trading 6.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is $0.32. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Cyclically Adjusted Book per Share is $0.32 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.17 is trading 6.8% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • Cyclically Adjusted Book per Share: $0.32
  • GF Value™: $6.62 vs. price of $6.17 (6.8% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.17
Price
$6.62
GF Value